# Hoffmann-La Roche: Phase 4 study closed enrollment, 136 enrolled (Severe Hemophilia A, Moderate Hemophilia A)

**Score:** 85/100

| Field | Value |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis |
| NCT ID | NCT05181618 |
| Phase | Phase 4 |
| Status | active not recruiting |
| Conditions | Severe Hemophilia A; Moderate Hemophilia A |
| Intervention types | drug |
| Target enrollment | 136 |
| Site countries | United States, Brazil, Canada, Germany, Hungary, Italy, Morocco, Serbia, Spain, Tunisia, Turkey (Türkiye), United Kingdom |
| Posted | 2022-01-06 |
| Planned start | 2022-06-20 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-23 |
| Last update posted | 2026-10-23 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- 136 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05181618). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.